Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) 股价在周二盘前交易中上涨3.8%，此前其合作伙伴荣昌生物 (RemeGen)报告了telitacicept在原发性干燥综合征三期研究中的48周积极结果。

在中国进行的为期48周的试验表明，接受泰利他西普160mg治疗的患者中有71.8%在24周时达到了疾病活动的临床显著减少，而安慰剂组患者仅为19.3%，这是通过EULAR干燥综合征疾病活动指数（ESSDAI）测量的。

格隆汇6月26日丨荣昌生物(09995.HK)发布公告，2025年6月25日， (i)公司及Vor Biopharma Inc.(“Vor Bio”)订立许可协议(“许可协议”)，据此，公司将具有自主知识产权的泰它西普(“许可产品”)有偿许可给Vor Bio，Vor Bio将获得在除大中华区(即中国大陆、中国香港、中国澳门 ...

Vor Biopharma Inc (NASDAQ:VOR) rose 3.8% in premarket trading Tuesday after its partner RemeGen announced encouraging 48-week ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) stock gained 3.8% in premarket trading Tuesday after its collaborator RemeGen reported positive 48-week results from a Phase 3 study of telitacicept in ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

What are the strange white cone structures located in fields and what do they have to do with aviation? Although they’ve been around since the 1930s and widely in use since the 1970s, Very High ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

Using the 2 Stage Free Cash Flow to Equity, Vor Biopharma fair value estimate is US$0.31 With US$0.32 share price, Vor Biopharma appears to be trading close to its estimated fair value Analyst price ...